Most cancer drugs never reach the brain. That leaves cancer in the central nervous system, whether it starts there or spreads there, among the least served areas in oncology. Reglagene is developing RGN6024, an oral, brain-penetrant small molecule that works on the primary tumor and on the metastases, including in the brain. It targets tubulin, a mechanism validated across many solid tumors but never made to work in the brain. In an intracranial glioma model, RGN6024 produced a 98% lower bioluminescent tumor signal than vehicle, with 100% survival (Mol Cancer Ther 2025;24:1129-1144). Full paper: https://doi.org/10.1158/1535-7163.MCT-24-1208 RGN6024 holds FDA Orphan Drug Designation. It has completed pharmacology, tolerability studies in two species, and GMP manufacturing process development. GLP toxicology and GMP manufacture stand between it and an IND. Founded in 2016 as a University of Arizona spinout. Based in Tucson, Arizona.
| Website | https://www.reglagene.com/ |
| Employees | 4 (3 on RocketReach) |
| Founded | 2016 |
| Address | 300 N. Main Ave. Suite 105, Tucson, Arizona 85701, US |
| Phone | +1 520-235-0365 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+8 more
(view full list)
|
| Industry | Biotechnology Research, Biotechnology, Science and Engineering, Life Science |
| Keywords | Neurological Disorders, Therapeutics, Drug Development, Biotechnology, Pharmaceutical, Central Nervous System, Neurology, Drug Delivery, Clinical Trials, New Therapies, Breakthrough Therapies, Innovative Medicines, Pharmaceutical Research, Treatment Development, Disease Treatment |
| Competitors | Thermo Fisher Scientific, Illumina, Agilent Technologies, Roche, QIAGEN, Bio-Rad Laboratories, PerkinElmer, Inc., KPL, Twist Bioscience, BGI Genomics +39 more (view full list) |
Looking for a particular Reglagene employee's phone or email?
Richard Austin is the CEO and Co-Founder of Reglagene.
3 people are employed at Reglagene.
Reglagene is based in Tucson, Arizona.